Table 1 Clinical and laboratory features of 123 Brazilian patients with primary gout
From: Nephrolithiasis in gout: prevalence and characteristics of Brazilian patients
Value | |
|---|---|
Male gender | 115 (93.5%) |
Skin color/race | |
White | 102 (82.9%) |
Brown or Black | 14 (11.4%) |
Asian | 7 (5.7%) |
Age (years) | 62.9 ± 09.4 |
Age at the onset of disease (years) | 44.9 ± 12.3 |
Duration of disease (years) | 18.2 ± 10.5 |
Tophi | 69 (56.1%) |
Underexcretion of uric acid | 110 (89.4%) |
Alcohol use disorder | 90 (73.2%) |
Current | 23 (18.7%) |
Past | 67 (54.5%) |
Smoking history | 63 (51.2%) |
Current | 10 (8.1%) |
Past | 53 (43.1%) |
Medication | |
Allopurinol | 45 (36.6%) |
Benzbromarone | 76 (61.8%) |
Potassium citrate | 13 (10.6%) |
Colchicine | 32 (26.0%) |
Glucocorticoids | 7 (5.7%) |
NSAIDs | 64 (52.0%) |
Antidiabetic medication | 18 (14.6%) |
Antihypertensives | 92 (74.8%) |
Lipid-lowering medication | 25 (20.3%) |
Serum creatinine (mg/dL) | 1.34 ± 0.55 |
Serum urea (mg/dL) | 44.1 ± 25.3 |
eGFR – CKD EPI (mL/min/1.73 m2) | 63.9 ± 21.7 |
Serum uric acid levels (mg/dL) | 7.13 ± 1.95 |
Uric acid clearance (mL/min) | 5.48 ± 3.91 |
Uric acid clearance < 6 mL/min | 85 (69.1%) |
Urinary uric acid excretion (g/24 h) | 0.53 ± 0.30 |
Serum glucose (mg/dL) | 105.7 ± 26.8 |
Serum total cholesterol (mg/dL) | 205.4 ± 49.4 |
Serum triglyceride (mg/dL) | 231.4 ± 399.6 |
Urinalysis | |
pH | 5.79 ± 0.83 |
Pyuria (> 10 leukocytes/HPF) | 6 (4.9%) |
Hematuria (> 3 erythrocytes/HPF) | 12 (9.8%) |
Significant proteinuria | 5 (4.1%) |